Dalbavancin in clinical practice: a particular place for the elderly?
- 26 April 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 41 (6), 977-979
- https://doi.org/10.1007/s10096-022-04427-2
Abstract
We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin’s administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients.Keywords
This publication has 11 references indexed in Scilit:
- Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of ViennaClinical Infectious Diseases, 2018
- Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016)International Journal of Antimicrobial Agents, 2018
- Dalbavancin in the treatment of different gram-positive infections: a real-life experienceInternational Journal of Antimicrobial Agents, 2017
- The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgeryJournal of Chemotherapy, 2017
- Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)European Journal of Clinical Microbiology & Infectious Diseases, 2016
- Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Therapeutics and Clinical Risk Management, 2016
- Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesDrug Safety, 2015
- In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance ProgramAntimicrobial Agents and Chemotherapy, 2015
- Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular TissueAntimicrobial Agents and Chemotherapy, 2015
- A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly PatientsJournal of the American Geriatrics Society, 2008